Clinical safety and primary efficacy of bone marrow mesenchymal cell transplantation in subacute spinal cord injured patients
Clinical safety and primary efficacy of bone marrow mesenchymal cell transplantation in subacute spinal cord injured patients
复制标题
DOI：
10.1016/j.clineuro.2012.02.003
复制
发表时间：
2012-09-01
影响因子：
1.9
通讯作者：
Eskandary, Hossein
中科院分区：
文献类型：
--
作者：
Karamouzian, Saeid;Nematollahi-Mahani, Seyed Noureddin;Eskandary, Hossein
背景资料：近年来，一些研究对不同来源的干细胞在脊髓损伤（SCI）患者中的作用进行了评价。本研究旨在探讨自体骨髓细胞（BMC）移植治疗胸段完全性脊髓损伤的可行性和治疗潜力。这项非随机临床试验比较了11例完全性SCI患者通过腰椎穿刺（LP）将自体BMC移植到脑脊液（CSF）中的结果，对照组20例，常规治疗，不进行骨髓基质细胞移植。使用美国脊髓损伤协会（ASIA）损伤量表对患者进行术前和随访神经功能评估。然后，参与者被随访12-33 months.Results：11例患者的平均年龄为33.2 +/- 8.9岁和20例患者的平均年龄为33.5 +/- 7.2岁，分别参加了研究和对照组。研究组和对照组患者在常规治疗和细胞移植后均未发生任何不良反应和并发症。11名患者中有5名研究组中有45.5%的患者和对照组中有3名患者（15%）显示出明显的恢复，但结果在统计学上处于临界状态（P=0.095）。我们的结论是，通过LP移植自体BMC是一种可行且安全的技术，但目前，关于临床潜力还没有明确的答案，尽管通过统计学观察到治疗SCI患者的潜在趋势。(C)2012爱思唯尔有限公司版权所有。
Background: In recent years, some studies were conducted to evaluate the effects of stem cells from different sources on patients with spinal cord injury (SCI). This study was carried out to evaluate the feasibility and therapeutic potential of autologous bone marrow cell (BMC) transplantation in 11 complete spinal cord injured patients at thoracic level.Methods and materials: This nonrandomized clinical trial compared the results of autologous BMC transplantation into cerebrospinal fluid (CSF) via lumbar puncture (LP) in 11 patients having complete SCI, with 20 patients as control group who received conventional treatment without BMC transplantation. The patients underwent preoperative and follow-up neurological assessments using the American Spinal Injury Association (ASIA) impairment scale. Then, the participants were followed for 12-33 months.Results: Eleven patients with the mean age of 33.2 +/- 8.9 years and 20 patients with the mean age of 33.5 +/- 7.2 years were enrolled in the study and in the control group, respectively. None of the patients in the study and control group experienced any adverse reaction and complications, neither after routine treatment nor after cell transplantation. Five patients out of 11(45.5%) in the study group and three patients in the control group (15%) showed marked recovery, but the result was statistically borderline (P=0.095).Conclusion: We conclude that transplantation of autologous BMC via LP is a feasible and safe technique, but at the moment, no clear answer can be given regarding the clinical potential, despite a potential tendency to treat SCI patients, observed through statistics. (C) 2012 Elsevier B.V. All rights reserved.